Comparing the current results to its competitors, Eiger Biopharmaceuticals Inc reported Revenue increase in the 4 quarter 2023 by 41.06 % year on year, while most of its competitors have experienced contraction in revenues by -3.21 %, achieved in the same quarter.
Eiger Biopharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in a highly competitive environment with numerous multinational pharmaceutical and large biotechnology firms developing or marketing products for similar indications. These competitors often possess greater financial, technical, and human resources, which may allow them to develop or market products that are more effective, safer, or less costly, obtain regulatory approvals more quickly, and achieve broader market acceptance. Industry mergers and acquisitions may further concentrate resources among fewer competitors. Competition also extends to securing qualified personnel, clinical study sites, patient enrollment, and complementary technologies. Smaller or early-stage companies can be significant competitors, particularly through collaborations with larger firms. Specifically, Gilead is identified as a competitor in the hepatitis D virus (HDV) market, holding conditional approval in Europe and having submitted a biologics license application (BLA) in the United States.
Strong sales growth of 41.06 % in Overall company contributed to Eiger Biopharmaceuticals Inc increase in total revenue by 41.06 % Eiger Biopharmaceuticals Inc improved its market share in this segment, to approximately 0.03 %.
Publicly Traded Peers of Eiger Biopharmaceuticals Inc
Vir Biotechnology Inc Share Performance
+20.00%
30 Days
Vir Biotechnology Inc
Profile
Vir Biotechnology Inc is a clinical-stage immunology company that focuses on developing and commercializing innovative treatments for infectious diseases. Their business model revolves around the discovery and development of antibody therapies and other immunological approaches to combat a wide range of viral pathogens. They collaborate with leading research institutions and pharmaceutical companies to accelerate the development and commercialization of their products.
In8bio Inc operates as a clinical-stage biotechnology company that focuses on developing transformative therapies for the treatment of cancer and other diseases. The company follows a research and development model centered on leveraging their proprietary platform to identify and optimize novel genetic circuits for targeted cell-based therapies.
Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.
4D Molecular Therapeutics Inc operates with a business model focused on developing innovative gene therapy products to address serious genetic diseases. The company utilizes its proprietary technology platform to design and optimize viral vectors for targeted gene delivery. With a strong commitment to research and development, 4D Molecular Therapeutics collaborates with partners in academia, industry, and patient organizations to advance transformative treatments for patients in need.
Sources:
Eiger Biopharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Eiger Biopharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
